A host of China stocks are recommended by investment analysts whether or not the economy gets a boost from measures taken this week to boost the sluggish domestic economy there. On Tuesday, the People's Bank of China announced a series of steps designed to lift the country's slumping economy.
On Sunday, Morgan Stanley analyst Terence Flynn initiated research coverage of the stock with an overweight rating and $118 price target, implying that shares could soar 168%. "Based on Ph1/2a data, we believe GSBR1290's profile is competitive to that of other oral diabesity drugs on the market and in development . We expect Ph2b obesity data for GSBR-1290 by YE25, representing the next catalyst for the program," Flynn wrote.
Wij hebben dit nieuws samengevat zodat u het snel kunt lezen. Bent u geïnteresseerd in het nieuws, dan kunt u hier de volledige tekst lezen. Lees verder: